RU2700083C2 - Применение генетически модифицированного патогенного вируса кори с улучшенными проапоптотическими свойствами (вирус mv-deltac) в терапии рака - Google Patents

Применение генетически модифицированного патогенного вируса кори с улучшенными проапоптотическими свойствами (вирус mv-deltac) в терапии рака Download PDF

Info

Publication number
RU2700083C2
RU2700083C2 RU2015128913A RU2015128913A RU2700083C2 RU 2700083 C2 RU2700083 C2 RU 2700083C2 RU 2015128913 A RU2015128913 A RU 2015128913A RU 2015128913 A RU2015128913 A RU 2015128913A RU 2700083 C2 RU2700083 C2 RU 2700083C2
Authority
RU
Russia
Prior art keywords
cells
deltac
cancer
tumor
strain
Prior art date
Application number
RU2015128913A
Other languages
English (en)
Russian (ru)
Other versions
RU2015128913A (ru
Inventor
Фредерик ТАНЖИ
Марк ГРЕГОРИ
Жан-Франсуа ФОНТЕНЮ
Жан-Баптист ЖУЛЛЕРМЕ
Шанталь КОМБРЕДЕ
Original Assignee
Институт Пастер
Сентре Натионал Де Ла Решерше Сиентифик
Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль
Университе Де Нант
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Институт Пастер, Сентре Натионал Де Ла Решерше Сиентифик, Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль, Университе Де Нант filed Critical Институт Пастер
Publication of RU2015128913A publication Critical patent/RU2015128913A/ru
Application granted granted Critical
Publication of RU2700083C2 publication Critical patent/RU2700083C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18432—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18461—Methods of inactivation or attenuation
    • C12N2760/18462—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2015128913A 2013-01-24 2014-01-20 Применение генетически модифицированного патогенного вируса кори с улучшенными проапоптотическими свойствами (вирус mv-deltac) в терапии рака RU2700083C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13305086.4A EP2759301A1 (en) 2013-01-24 2013-01-24 Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus)
EP13305086.4 2013-01-24
PCT/EP2014/051063 WO2014114605A1 (en) 2013-01-24 2014-01-20 Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (mv-deltac virus) in cancer therapy

Publications (2)

Publication Number Publication Date
RU2015128913A RU2015128913A (ru) 2017-03-02
RU2700083C2 true RU2700083C2 (ru) 2019-09-12

Family

ID=47683672

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015128913A RU2700083C2 (ru) 2013-01-24 2014-01-20 Применение генетически модифицированного патогенного вируса кори с улучшенными проапоптотическими свойствами (вирус mv-deltac) в терапии рака

Country Status (11)

Country Link
US (3) US9889193B2 (cg-RX-API-DMAC7.html)
EP (2) EP2759301A1 (cg-RX-API-DMAC7.html)
JP (1) JP6382223B2 (cg-RX-API-DMAC7.html)
CN (1) CN107223055A (cg-RX-API-DMAC7.html)
BR (1) BR112015017692B1 (cg-RX-API-DMAC7.html)
CA (1) CA2898370C (cg-RX-API-DMAC7.html)
DK (1) DK2948157T3 (cg-RX-API-DMAC7.html)
ES (1) ES2700749T3 (cg-RX-API-DMAC7.html)
PL (1) PL2948157T3 (cg-RX-API-DMAC7.html)
RU (1) RU2700083C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014114605A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2759301A1 (en) * 2013-01-24 2014-07-30 Institut Pasteur Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus)
CN107085095A (zh) * 2017-03-02 2017-08-22 江苏华冠生物技术股份有限公司 用作酶联试剂盒包被抗原的麻疹病毒裂解液的制备方法
US11633441B2 (en) 2017-12-01 2023-04-25 Gerd Sutter Immuno-modulated replication-efficient vaccinia virus strain
CN117323421A (zh) * 2022-06-24 2024-01-02 中国医学科学院医学生物学研究所 一种流感病毒介导的抗肿瘤疫苗及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012022495A1 (en) * 2010-08-20 2012-02-23 Lauer Ulrich M Oncolytic measles virus

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118740B1 (en) 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
EP1375512B1 (en) 2002-06-20 2009-07-22 Institut Pasteur Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
CA2508266A1 (fr) 2005-06-20 2006-12-20 Institut Pasteur Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
DK1939214T3 (da) 2006-12-22 2013-10-14 Pasteur Institut Celler og metodik til at generere ikke-segmenterede negativstrengede RNA-vira
EP2058003A1 (en) * 2007-10-10 2009-05-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Medicaments and methods for treating mesothelioma
US9399062B2 (en) * 2011-01-18 2016-07-26 Christopher D. Richardson PVRL4 (Nectin4) is a receptor for measles virus
EP2759301A1 (en) * 2013-01-24 2014-07-30 Institut Pasteur Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012022495A1 (en) * 2010-08-20 2012-02-23 Lauer Ulrich M Oncolytic measles virus

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
FRANK RADECKE et al., The Nonstructural C Protein Is Not Essential for Multiplication of Edmonston B Strain Measles Virus in Cultured Cells, VIROLOGY 1996, Vol.217, pp. 418-421. *
FRANK RADECKE et al., The Nonstructural C Protein Is Not Essential for Multiplication of Edmonston B Strain Measles Virus in Cultured Cells, VIROLOGY 1996, Vol.217, pp. 418-421. KAORU TAKEUCHI et al., Stringent Requirement for the C Protein of Wild-Type Measles Virus for Growth both In Vitro and in Macaques, JOURNAL OF VIROLOGY, June 2005, Vol. 79, No. 12, pp.7838-7844. JEAN-BAPTISTE GUILLERME et al., Measles Virus Vaccine-Infected Tumor Cells Induce Tumor Antigen Cross-Presentation by Human Plasmacytoid Dendritic Cells, Clin Cancer Res January 21, 2013, Vol.19, No.5, pp.1147-1159. *
GUY UNGERECHTS et al., Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics, Gene Ther. 2010 December ; 17(12): 1506-1516. *
GUY UNGERECHTS et al., Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics, Gene Ther. 2010 December ; 17(12): 1506-1516. Ю.И. АММУР и др., ВИРУС КОРИ КАК ОНКОЛИТИЧЕСКИЙ АГЕНТ, Вопросы вирусологии, 2013, S1, стр.116-131. *
JEAN-BAPTISTE GUILLERME et al., Measles Virus Vaccine-Infected Tumor Cells Induce Tumor Antigen Cross-Presentation by Human Plasmacytoid Dendritic Cells, Clin Cancer Res January 21, 2013, Vol.19, No.5, pp.1147-1159. *
KAORU TAKEUCHI et al., Stringent Requirement for the C Protein of Wild-Type Measles Virus for Growth both In Vitro and in Macaques, JOURNAL OF VIROLOGY, June 2005, Vol. 79, No. 12, pp.7838-7844. *
Ю.И. АММУР и др., ВИРУС КОРИ КАК ОНКОЛИТИЧЕСКИЙ АГЕНТ, Вопросы вирусологии, 2013, S1, стр.116-131. *

Also Published As

Publication number Publication date
JP2016506722A (ja) 2016-03-07
US9889193B2 (en) 2018-02-13
US10980873B2 (en) 2021-04-20
CN107223055A (zh) 2017-09-29
BR112015017692A2 (pt) 2019-11-19
ES2700749T3 (es) 2019-02-19
WO2014114605A1 (en) 2014-07-31
JP6382223B2 (ja) 2018-08-29
RU2015128913A (ru) 2017-03-02
DK2948157T3 (en) 2019-01-07
US10314905B2 (en) 2019-06-11
US20180221469A1 (en) 2018-08-09
US20200016260A1 (en) 2020-01-16
PL2948157T3 (pl) 2019-03-29
US20150359873A1 (en) 2015-12-17
EP2948157A1 (en) 2015-12-02
EP2948157B1 (en) 2018-10-10
EP2759301A1 (en) 2014-07-30
CA2898370C (en) 2020-01-14
BR112015017692B1 (pt) 2021-11-03
CA2898370A1 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
Gauvrit et al. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response
CA3030451C (en) Compositions and methods for alphavirus vaccination
KR20170003920A (ko) 종양분해성 백시니아 바이러스
JP2018519847A (ja) 免疫優性アデノウイルスエピトープに突然変異を有する腫瘍溶解性アデノウイルスおよび癌処置におけるそれらの使用
US10980873B2 (en) Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-deltaC virus) in cancer therapy
US20230248819A1 (en) Nucleic acid lipid particle vaccine
US20200246443A1 (en) Therapeutic cancer vaccine targeted to haah (aspartyl-[asparaginyl]-beta-hydroxylase)
JP2017509652A (ja) 細胞性の細胞傷害性免疫応答を誘導または延長する方法における使用のための医薬
JP2023523423A (ja) SARS-CoV-2に対するワクチン及びその調製物
JP2021516957A (ja) パラポックスウイルスベクター
US9636395B2 (en) Medicaments and methods for treating mesothelioma
CN116650633A (zh) 冠状病毒疫苗
CA2615687A1 (en) Immune response inducing preparations
HK40097472A (en) Coronavirus vaccine
KR20250089555A (ko) 면역요법 조성물 및 사용 방법
HK40116087A (en) Oncolytic virus simultaneously expressing cd55 and cd59
CN108239660B (zh) 一种重组结核病疫苗,其制备方法及应用
WO2024062098A1 (en) Recombinant pseudocowpox virus encoding an interleukin-12